Eric Keith Rowinsky
Impact in
- Otorhinolaryngology top 0.05%
- Head and Neck Cancer Studies
- Oncology top 0.1%
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
Papers in
- Oncology 158
- Cancer Treatment and Pharmacology 88
- Colorectal Cancer Treatments and Studies 36
- HER2/EGFR in Cancer Research 16
-
- Cancer therapeutics and mechanisms 97
- Co-authors
- Ross C. Donehower (72 shared papers)Hagop Youssoufian (16 shared papers)Manuel M. Hidalgo (25 shared papers)Roger B. Cohen (4 shared papers)David S. Ettinger (27 shared papers)J. Giralt (4 shared papers)José Baselga (4 shared papers)James A. Bonner (4 shared papers)
- Journals
- Journal of Clinical Oncology (63 papers)Clinical Cancer Research (33 papers)Investigational New Drugs (17 papers)Blood (16 papers)Annals of Oncology (16 papers)
- Partner nations
- United StatesSpainCanada
In The Last Decade
Eric Keith Rowinsky
349 papers receiving 35.1k citations
Eric Keith Rowinsky's Hit Papers
Peers
Comparison fields: 5 of 153
- Otorhinolaryngology 3.8k
- Oncology 9.8k
- Pulmonary and Respiratory Medicine 5.8k
- Biomaterials 1.8k
- Reproductive Medicine 1.4k
Countries citing papers authored by Eric Keith Rowinsky
This map shows the geographic impact of Eric Keith Rowinsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Keith Rowinsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Keith Rowinsky more than expected).
Fields of papers citing papers by Eric Keith Rowinsky
This network shows the impact of papers produced by Eric Keith Rowinsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Keith Rowinsky. The network helps show where Eric Keith Rowinsky may publish in the future.
Co-authors
The 25 scholars most cited alongside Eric Keith Rowinsky, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 352 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck Hit paper breakdown → | 2006 | 4134 |
| 2 | Paclitaxel (Taxol) Hit paper breakdown → | 1995 | 1674 |
| 3 | Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Hit paper breakdown → | 2009 | 1565 |
| 4 | Taxol: A Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial Neoplasms Hit paper breakdown → | 1989 | 967 |
| 5 | Taxol: A Novel Investigational Antimicrotubule Agent Hit paper breakdown → | 1990 | 943 |
| 6 | Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer Hit paper breakdown → | 2004 | 924 |
| 7 | Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies Hit paper breakdown → | 2001 | 883 |
| 8 | Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2006 | 859 |
| 9 | ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial Hit paper breakdown → | 2002 | 684 |
| 10 | 1997 | 647 | |
| 11 | Clinical toxicities encountered with paclitaxel (Taxol). | 1993 | 620 |
| 12 | 2003 | 577 | |
| 13 | 1993 | 567 | |
| 14 | 2000 | 514 | |
| 15 | Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial Hit paper breakdown → | 2000 | 503 |
| 16 | 2010 | 483 | |
| 17 | 1999 | 458 | |
| 18 | 2006 | 448 | |
| 19 | 2018 | 404 | |
| 20 | 1991 | 374 |
About Eric Keith Rowinsky
Eric Keith Rowinsky is a scholar working on Oncology, Molecular Biology, Pharmacology, Hematology and Pulmonary and Respiratory Medicine, having authored 352 papers that have together received 37k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (97 papers), Cancer Treatment and Pharmacology (88 papers), Colorectal Cancer Treatments and Studies (36 papers), Pharmacogenetics and Drug Metabolism (30 papers), Acute Myeloid Leukemia Research (16 papers), HER2/EGFR in Cancer Research (16 papers), Lung Cancer Treatments and Mutations (16 papers) and Ovarian cancer diagnosis and treatment (13 papers). The work is most often cited by research in Otorhinolaryngology (3.8k citations), Oncology (9.8k citations), Pulmonary and Respiratory Medicine (5.8k citations), Biomaterials (1.8k citations) and Reproductive Medicine (1.4k citations). Eric Keith Rowinsky has collaborated with scholars based in United States, Spain and Canada. Frequent co-authors include Ross C. Donehower, Hagop Youssoufian, Manuel M. Hidalgo, Roger B. Cohen, David S. Ettinger, J. Giralt, José Baselga, James A. Bonner, Paul M. Harari and Ranjan Kumar Sur. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Investigational New Drugs, Blood and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.